At CTO West Coast, an expert discussed the implications of the FDA’s expedited approval programmes with a spotlight on ...

The Global Biologics CDMO Market is expected to witness a growth rate of 14-16% in the next five years. Growing ...

FDA biosimilar approvals reached a record 19 in 2024, with projections indicating that 2025 could surpass this milestone ...

Under a new executive order, prescription drug prices will be reduced “almost immediately.” President Donald Trump, in a ...

BURLINGAME, CA, UNITED STATES, May 20, 2025 /EINPresswire.com/ -- Biotechnology Market is estimated to be valued at USD 1,034.63 Bn in 2025 and is expected to reach USD 2,330.47 Bn in 2032, exhibiting ...

AI-powered tools are enhancing precision, efficiency, and decision-making in biopharmaceutical development. Recently, Jared ...

Lantern's proprietary RADR ® platform has grown during Q1 2025 to approximately 200 billion oncology-focused data points across multiple sources (proprietary, collaborative and public) of oncology, ...

About Cingulate Inc. Cingulate Inc. (NASDAQ: CING), is a biopharmaceutical company utilizing ... beliefs and objectives with respect to product development, clinical studies, clinical and regulatory ...

a biopharmaceutical contract development and manufacturing organization (CDMO), today announced the expansion of its protein-based and gene therapy service offerings with the addition of Viral ...

Accelerated Delivery Timelines - Over One Month ... from cell line construction and process development to cGMP manufacturing of biopharmaceutical products. The company's extensive expertise ...

“He brings a wealth of biopharmaceutical expertise ... risks related to Vaxcyte’s product development programs, including development timelines, success and timing of chemistry, manufacturing ...